Dova Pharmaceuticals — Corporate Update (May 2018)
14 slides from Dova Pharmaceuticals's corporate update, May 21, 2018
Slide 1: Disclaimer
Disclaimer Certain information contained in this presentation relates to or is based on studies, surveys and other data obtained from third-party sources and Dova’s own internal estimates and research. While Dova believes these sources to be reliable as of the date of this presentation, it has not i
Slide 2: Topics for Discussion
Topics for Discussion • • • • • DOPTELET Approved Packaging and Labelling Addressing a Market with Unmet Needs Launch Plans / Launch Metrics Additional Important Milestones in 2018 Q&A 3
Slide 3: DOPTELET (avatrombopag) tablets packaging
Rx Only HOC71J0020 1S NDC1Utt0l0 10 R.IOnly Doptelet. (avatrombopag)tablets 20mg Doptelet. (avatrombopag)tablets 20mg ·=···•·•.D •: •:lova 4 •••.• PHARIIA AC E UTICALS
Slide 4: DOPTELET Indication and Important Safety Information
DOPTELET Indication Indication: DOPTELET (avatrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS DOPTELET is a thro
Slide 5: Approval driven by consistent results from two randomized controlled trials
Approval was driven by consistent results from two randomized controlled trials (n=435) PROPORTION OF PATIENTS WHO DID NOT REQUIRE PLATELET TRANSFUSION OR ANY RESCUE PROCEDURE FOR BLEEDING ADAPT-1 / ADAPT-2 (<40K / µL) ADAPT-1 / ADAPT-2 (>40K / µL to <50K / µL) ADAPT-1 / ADAPT-2 (<35K / µL) P < 0.00
Slide 6: DOPTELET: A significant improvement compared to the current standard of care
DOPTELET: A significant improvement compared to the current standard of care POTENTIAL TRANSFUSION RISKS RISK OF ANTIBODY DEVELOPMENT • May lead to refractoriness in up to ~50% of patients 70K - 210K* SCHEDULED PROCEDURES FOR CHRONIC LIVER DISEASE PATIENTS WITH PLATELET COUNTS < 50,000 / µL RISK OF
Slide 7: DOPTELET Launch Plan is prepared for a June launch
DOPTELET Launch Plan is prepared for a June launch MSL Team Specialty Pharmacies Distributors HEPATOLOGIST National Account Manager Team Managed Care Organizations Sales Team 8
Slide 8: Experienced and Dedicated Sales Force
Experienced and Dedicated Sales Force • • All sales territories have been filled Over 300 years experience in hepatology / liver disease Previous hepatology experience includes Salix, BMS, Gilead, Intercept Sales Force Training currently underway in preparation for a June launch • • 9
Slide 9: Dova 1Source: Streamlining access for patients and healthcare providers
Dova 1Source: Streamlining access for both patients and healthcare providers MANAGES THE LOGISTICS COORDINATES FINANCIAL SUPPORT DELIVERS DOPTELET ON TIME FOR PROCEDURE / SUPPORTS ADHERENCE 10
Slide 10: ··-T·a--i-CI-IC·C-IIT-a-.l·\'W-I-M·P-TB-.nT-&afll ·==c=:."U:tl.:........ ··-·--. --;':::-.:.:=·'-".'-..-...-...-...…
··-T·a--i-CI-IC·C-IIT-a-.l·\'W-I-M·P-TB-.nT-&afll ·==c=:."U:tl.:........ ··-·--. --;':::-.:.:=·'-".'-..-...-...-....----.....-..---·-·-·-···.·..-··-· ... A - - --.•.. .X... ..... .J ac,p:.,.,, D oPtelet. -·-a., ·.__-.._--_._--_-_-------...._, ... ·--·------------- ---::---------·-----·-----·-·-·
Slide 11: DOPTELET: Strong Conference Presence in 2018
DOPTELET: Strong Conference Presence in 2018 • Digestive Disease Week (DDW) June 2-5, Washington, DC American College of Gastroenterology (ACG) October 5-10, Philadelphia, PA American Association for the Study of Liver Diseases (AASLD) November 9-13, San Francisco, CA American Society of Hematology
Slide 12: Near-term launch metrics Dova intends to track and report
Dova intends to track and report out on the following near-term launch metrics 1. 2. 3. 4. 5. Number of Unique Prescribers in the quarter % of Doptelet referrals converting to patient shipment Reach and Frequency with our Target Audience & Target Institutions Average time (in days) for commercial pa
Slide 13: Several important anticipated milestones remaining in 2018
Several important anticipated milestones remaining in 2018 First Patients In (FPI) in Chemotherapy-Induced Thrombocytopenia (CIT) Trial (Q2 ‘18) 2018 Product Availability / Pricing sNDA filed with FDA for chronic ITP indication (H2 ‘18) April 27, 2018 Marketing Authorization Application (MAA) filed
Slide 14: Several important anticipated milestones remaining in 2018
Several important anticipated milestones remaining in 2 First Patients In (FPI) in Chemotherapy-Induced Thrombocytopenia (CIT) Trial (Q2 18) 2018 Prodi Availability April 27,2018 / Pricing sNDA filed with FDA for Marketing chronic ITP indication Authorization (H2 ‘18) Application (MAA) filed with th